• All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic 

      Alnuaimi, Asma A.; Chemaitelly, Hiam; Semaan, Sandy; Almukdad, Sawsan; Al-Kanaani, Zaina; ... more authors ( BMJ Publishing Group , 2023 , Article)
      Objective To investigate all-cause mortality, COVID-19 mortality and all-cause non-COVID-19 mortality in Qatar during the COVID-19 pandemic. Methods A national, retrospective cohort analysis and national, matched, retrospective ...
    • Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population 

      Nasrallah, Gheyath K; Dargham, Soha R; Shurrab, Farah; Al-Sadeq, Duaa W; Al-Jighefee, Hadeel; ... more authors ( Nature Research , 2021 , Article)
      Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological ...
    • Antibiotic Prescription Patterns for Upper Respiratory Tract Infections in Outpatient Qatari Population in the Private Sector 

      Butt, Adeel Ajwad; Navasero, Cristina S.; Thomas, Bright; Al Marri, Salih; Al Katheeri, Huda; ... more authors ( Elsevier , 2016 , Article)
      Background: Antibiotic are often inappropriately prescribed for upper respiratory infections (URI) in the Western countries. Data on the proportion of inappropriate prescriptions are lacking from the Middle East and other ...
    • Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting 

      Abu-Raddad, Laith J.; Chemaitelly, Hiam; Malek, Joel A.; Ahmed, Ayeda A.; Mohamoud, Yasmin A.; ... more authors ( NLM (Medline) , 2021 , Article)
      BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed ...
    • Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ( American Medical Association , 2021 , Article)
      The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 ...
    • Associations of Vaccination and of Prior Infection with Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar 

      Bertollini, Roberto; Chemaitelly, Hiam; Yassine, Hadi M.; Al-Thani, Mohamed H.; Al-Khal, Abdullatif; ... more authors ( American Medical Association , 2021 , Other)
      The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by ...
    • Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections 

      Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Faust, Jeremy S.; Tang, Patrick; ... more authors (2023 , Article)
      In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...
    • BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. 

      Tang, Patrick; Hasan, Mohammad R; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ( Nature Researc , 2021 , Article)
      With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...
    • BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; Yassine, Hadi M.; ... more authors ( Elsevier , 2023 , Other)
      COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression ...
    • Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic 

      Abu-Raddad, Laith J.; Chemaitelly, Hiam; Ayoub, Houssein H.; Al Kanaani, Zaina; Al Khal, Abdullatif; ... more authors ( springer nature , 2021 , Article)
      The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a ...
    • Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant 

      Butt, A.A.; Butt, Adeel A.; Dargham, Soha R.; Loka, Srusvin; Shaik, Riyazuddin M.; ... more authors ( NLM (Medline) , 2022 , Article)
      SHORT SUMMARY: Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant. Those 6 to <18 years also have less severe ...
    • COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar 

      J. Abu-Raddad, Laith; Dargham, Soha; Chemaitelly, Hiam; Coyle, Peter; Al Kanaani, Zaina; ... more authors ( Public Library of Science , 2022 , Article)
      We developed a Coronavirus Disease 2019 (COVID-19) risk score to guide targeted RTPCR testing in Qatar. The Qatar national COVID-19 testing database, encompassing a total of 2,688,232 RT-PCR tests conducted between February ...
    • Covid-19 Vaccine Protection among Children and Adolescents in Qatar. 

      Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...
    • Darunavir-Cobicistat versus Lopinavir-Ritonavir for COVID-19 Pneumonia: Qatar's Experience 

      Elmekaty, Eman Zeyad I.; Alibrahim, Rim; Hassanin, Rania; Eltaib, Sitelbanat; Elsayed, Ahmed; ... more authors ( Hamad bin Khalifa University Press (HBKU Press) , 2022 , Article)
      Background: Coronavirus Disease 2019 (COVID-19) was first discovered in China and resulted in a pandemic crisis. 1,2 Many agents were investigated with inconclusive outcomes. 3 This study was conducted to compare the ...
    • Detection of Antinuclear Antibodies Targeting Intracellular Signal Transduction, Metabolism, Apoptotic Processes and Cell Death in Critical COVID-19 Patients 

      Nasarallah, Gheyath K.; Fakhroo, Aisha D.; Khan, Taushif; Cyprian, Farhan S.; Al Ali, Fatima; ... more authors ( Universita Cattolica del Sacro Cuore , 2022 , Article)
      Background and Objectives: The heterogeneity of the coronavirus disease of 2019 (COVID-19) lies within its diverse symptoms and severity, ranging from mild to lethal. Acute respiratory distress syndrome (ARDS) is a leading ...
    • Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease 

      Bansal, Devendra; Abdulmajeed, Jazeel; Al-Shamali, Maha H.M.A.; Albayat, Soha S.A.; Himatt, Sayed M.; ... more authors ( MDPI , 2022 , Article)
      Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed ...
    • Duration of immune protection of SARS-CoV-2 natural infection against reinfection. 

      Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ( Oxford University Press , 2022 , Article)
      The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...
    • Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. 

      Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ( Nature Research , 2022 , Article)
      SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...
    • Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...
    • Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar 

      Elias, Tayar; Abdeen, Sami; Abed Alah, Muna; Chemaitelly, Hiam; Bougmiza, Iheb; ... more authors ( Elsevier , 2023 , Article)
      BackgroundSome studies have reported that influenza vaccination is associated with lower risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) morbidity ...